

Personal Information



Narongsak Kiatikajornthada

Address: Bumrungrad Hospital

Country: Thailand

Curriculum Vitae

College Education:

- 1962-1963 Trium Udom Suksa School, Bangkok
- 1963-1965 Faculty of Science, Mahidol University
- 1965-1969 Faculty of Medicine, Mahidol University

Post Graduate:

- 1969-1970 Rotating Intern, Vajira Hospital, Bangkok, Thailand
- 1970-1971 Rotating Intern (Major Medicine), Fordham Hospital, Bronx, New York
- 1971-1973 Medical Resident, The Bronx-Lebanon Hospital
Center Affiliated with Albert Einstein College of Medicine, Bronx, New York
- 1973-1975 Fellow in Hematology, The Bronx-Lebanon Hospital Center, Bronx, New York
- 1975-1978 Private Practice Limited to Internal Medicine, Hematology and Oncology at Hays, Kansas, U.S.A.

Professional Appointment:

- 1974 Medical Attending Physician, Metropolitan New York
Medical College Affiliation, New York
- 1975-1978 Medical Staff at St. Anthony and Hadley Regional Hospital, Hays, Kansas
- 1975 Chief of Service ICU-CCU Internal Medicine, St. Anthony Hospital, Hay, Kansas
- 1975-1976 Secretary of Executive Committee, St. Anthony Hospital, Hays, Kansas
- 1977 Vice-Chief of Staff, St. Anthony Hospital, Hays, Kansas
- 1978-1980 Faculty Staff, Hematology Section, Department of Medicine.
Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- 1979-2001 Consulting Physician in Internal Medicine, Hemato-Oncology, Samitivej Hospital, Bangkok, Thailand

- 1990 Member of Subcommittee Medical Oncology, the Royal College of Physicians of Thailand
- 1996 One of the founders of the Thai Society of Clinical Oncology
- 2001 Consultant to Cancer Clinical Trial Ethic Committee, Ministry of Public Health
- 2002-2004 Vice President of the Thai Society of Clinical Oncology
- 2001-Present Co-Director, Horizon Regional Cancer Center at Bumrungrad Hospital, Bangkok, Thailand**
- 2003-2006 Elected Chairman of Department of Medicine, Bumrungrad Hospital, Bangkok, Thailand
- 2003-2006 Member of Medical Executive Committee, Bumrungrad Hospital Bangkok, Thailand
- 2004-Present Consultant to the Thai Society of Clinical Oncology

Past Company Appointment:

- 1990-1992 Assistant Business Director, Samitivej Hospital
- 1992-1994 Deputy Business Director, Samitivej Hospital
- 1995-1996 Deputy Hospital Director, Samitivej Sukumvit Hospital
- 1996-2000 President, Samitivej Public Company Limited
- 1991-2000 Director, Executive Board, Samitivej Public Company Limited
- 1992-2000 Director, Executive Board, Ruampatsriracha Company Limited

Medical Diploma, Certificates and Licenses :

- 1969 Diploma as Doctor of Medicine by Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
- 1973 Medical Licensure (FLEX) to Practice Medicine & Surgery in Illinois, New Jersey, New York, Kansas and California
- Medical Resident and Chief Resident Certificate,
The Bronx-Lebanon Hospital, Bronx, New York
- 1974 Diplomate, American Board of Internal Medicine
- 1976 Diplomate, American Board Subspecialty of Hematology
- 1997 Certificate, Thai Board of Medical Oncology
- 1995 Certificate, “Finance Accounting and Marketing Management” Faculty of Commerce and Accountancy, Thammasat University
- Certificate, “Organization and Human Resource Management”
Faculty of Commerce and Accountancy , Chulalongkorn University

Publications :

- Erythroleukemia-Reticulum Cell Sarcoma, Journal of Kansas Medical Society, V.78, No.7, July 1977
- Infectious Complications of Malignant Lymphoma, Ramathibodi Medical Journal, V.2, No.2, 1979

Hazards of Blood Transfusion, Ramathibodi Medical Journal,
V.4, No.1, Jan-Mar, 1981

Contributor - Text Book of Hematology by Thanomsri Srichaiyakul, 1986

Chapter 1 - Blood and Hematopoiesis

Chapter 2 - Erythropoietin and Anemia

Chapter 17 - The clinical Usage of cancer chemotherapy

Clinical Trial Experience

1. A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma.
2. An expanded access program of TarcevaTM (Erlotinib) in patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC).
3. A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) with/without Intravenous Bevacizumab (Q3W) versus Bolus and Continuous Infusion Fluorouracil / Intravenous Leucovorin with Intravenous Oxaliplatin (Q2W) (“FOLFOX-4”) with/without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients with Metastatic Colorectal Cancer.
4. An Open Label, Randomised, Parallel Group, Multicentre,Phase III Study to Assess Efficacy, Safety and Tolerability of Gefitinib (IRESSATM) (250mg tablet) Versus Carboplatin / Paclitaxel Doublet Chemotherapy as First-Line Treatment in Selected Patients with Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) in Asia.

Membership :

1. Thai Medical Council
2. Thai Medical Society
3. Thai Society of Clinical Oncology
4. The Royal College of Physician of Thailand
5. American Society of Clinical Oncology
6. ESMO

GCP Training :

2004	GCP Training by Roche
2005	GCP Training by Roche
2006	GCP Training by Astra Zeneca
2008	GCP Training by Bayer HealthCare
Nov 2011	GCP Training by CITI Collaborative Institutional Training Initiative